Short description
Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.
Description
Artielle ImmunoTherapeutics, Inc., a biopharmaceutical company, develops recombinant T-cell receptor ligands (RTLs) to treat T-cell mediated inflammatory diseases. It develops RTL1000, a compound for the treatment of multiple sclerosis. The company focuses on the development of therapeutics for the treatment of autoimmune diseases that include multiple sclerosis, celiac disease, type 1 diabetes, rheumatoid arthritis, uveitis, stroke, optic neuritis, and other diseases. Artielle ImmunoTherapeutics, Inc. was founded in 2004 and is based in Tigard, Oregon.
Last funding
Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
San Mateo, California, United States, North America
Founded on
January 1, 2004
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
No Way, Noway Youcantaccess, Blurry Noaccess, Nopepepe
Sign in for full access
Founders
Arthur Vandenbark, Halina Offner